A phase II study on third-line chemotherapy combined bevacizumab with S-1 for metastatic colorectal cancer with mutated KRAS: SAVIOR study.
Akinori Takagane
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Yasuhiro Miyake
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Kouji Kobayashi
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Naoki Nagata
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Atsushi Sato
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Yutaka Ogata
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Mutsumi Fukunaga
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Koki Otsuka
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Takao Takahashi
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Hidetomo Matsumoto
Research Funding - Taiho Pharmaceutical
Yuji Negoro
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Yoshihiro Matsubara
No relevant relationships to disclose
Motoki Yoshida
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical